1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Stem Cells Transplantation in Oncology -Pipeline Insights, 2015

Summary
DelveInsight’s, “Stem Cells Transplantation in Oncology -Pipeline Insights, 2015”, report provides comprehensive insights about pipeline drugs across this mode of therapy. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Stem Cells Oncology.
- The Report gives insights on 20+ products with 15+ companies, which are active in this field.
- In depth analysis of pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages.
- Comparative study of drugs under development.
- Therapeutics assessment by monotherapy and combination products and molecule type drug information, drug origin and mode of therapy.
- R&D activities and technologies used along with the pipeline therapies in development.
- Information related to collaborations in Stem Cells Transplantation Industry.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Please note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated mode of therapy.

Scope
- A snapshot of the global Stem Cell Transplantation therapy market scenario.
- Coverage of stem cell transplantation therapies under development across the globe
- Competitive landscape of investigational products in Stem Cells Therapy
- Detailed information on product description and related stage of development, the mode of therapy, mechanism of action, licensors & collaborators, development partner and technology information

Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Stem Cell therapy
- Devise corrective measures for pipeline projects by understanding therapy area specific to Stem Cell Transplantation therapies
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Understand the market and choose right partners for in-licensing and out licensing for your valuable assets
- Identifying the upcoming leaders in the Stem Cell Transplantation for oncology market in the coming years.
- Understand the factors behind failed/discontinued projects and move ahead without leaving any stone unturned

Table Of Contents

Stem Cells Transplantation in Oncology -Pipeline Insights, 2015
- Stem Cell Overview
- Types of stem cell transplants for treating cancer
- Allogeneic and Autologous Transplant
- Future of Stem Cells Transplantation in Oncology
- Current Market Senario
- Stem Cell Transplantation Analysis
- Stem Cells Therapy - Origin
- Stem Cells Therapy - Mode of Therapy
- Stem Cells Therapy - Technology
- Stem Cell Transplantation in Oncology Overview
- Pipeline Therapeutics
- An Overview of Pipeline Products for Stem Cell Oncology
- Therapeutics under Development by Companies
- Last Stage Products (Phase III and Filed)
- Comparative Analysis
- Drug 1
- Product Description:
- Research and Development
- Mid Stage Products (Phase II)
- Comparative Analysis
- Drug 2
- Product Description
- Research and Development
- Early Stage Products (Phase I and IND)
- Comparative Analysis
- Drug 3
- Product Description
- Research and Development
- Discovery and Pre-clinical stage Products
- Comparative Analysis
- Drug 4
- Product Description
- Research and Development
- Therapeutic Assessment
- Assessment by Monotherapy Products
- Assessment by Route of Administration
- Assessment by Source of Stem Cells
- Assessment by Mode of Therapy
- Assessment by Drug Origin
- Discontinued Products
- Dormant Products
- Methodology
- Consulting Services
- About DelveInsight
- Contact Us
- Disclaimer

List of Tables
Table 1: Companies with Stem cells Technology, 2015
Table 2: Stem Cell Therapies Developed using Technology, 2015
Table 3: Total Number of Stem Cells, 2015
Table 4: Number of Products under Development for Stem Cell Oncology, 2015
Table 5: Number of Products under Development by Companies, 2015
Table 6: Last Stage Products (Phase III and Filed), 2015
Table 7: Mid Stage Products (Phase II), 2015
Table 8: Early Stage Products (Phase I and IND), 2015
Table 9: Discovery and Pre-clinical Stage Products, 2015
Table 10: Assessment by Monotherapy Products, 2015
Table 11: Assessment by Route of Administration, 2015
Table 12: Assessment by Stage and Route of Administration, 2015
Table 13: Assessment by Source of stem Cell, 2015
Table 14: Assessment by Mode of Therapy, 2015
Table 15: Assessment by Stage and Mode of Therapy, 2015
Table 16: Assessment by Drug Origin, 2015
Table 17: Assessment by Stage and Drug Origin, 2015
Table 18: Discontinued Products, 2015
Table 19: Dormant Products, 2015

List of Figures
Figure 1: Number of Stem Cell Therapies by Origin, 2015
Figure 2: Number of Stem Cell Therapies by Mode of Therapy, 2015
Figure 3: Stem Cell Technology Analysis by Companies and Number of Therapies, 2015
Figure 4: Total Number of Stem Cells, 2015
Figure 5: Number of Products under Development for Stem Cell Oncology, 2015
Figure 6: Last Stage Products (Phase III and Filed), 2015
Figure 7: Mid Stage Products (Phase II), 2015
Figure 8: Early Stage Products (Phase I and IND), 2015
Figure 9: Discovery and Pre-clinical Stage Products, 2015
Figure 10: Assessment by Monotherapy Products, 2015
Figure 11: Assessment by Route of Administration, 2015
Figure 12: Assessment by Stage and Route of Administration, 2015
Figure 13: Assessment by Source of Stem Cells, 2015
Figure 14: Assessment by Mode of Therapy, 2015
Figure 15: Assessment by Stage and Mode of Therapy, 2015
Figure 16: Assessment by Drug Origin, 2015
Figure 17: Assessment by Stage and Drug origin, 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
OpportunityAnalyzer: Hyperparathyroidism - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Hyperparathyroidism - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

OpportunityAnalyzer: Hyperparathyroidism - Opportunity Analysis and Forecasts to 2025 Summary Hyperparathyroidism (HPT) is a common endocrinal disorder characterized by excessive plasma levels of parathyroid ...

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Human Epidermal growth factor Receptor type 2 (HER2-) breast cancer is the second ...

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025 Summary Hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market and Cardiovascular Disease Statistics in the US

  • March 2017
    30 pages
  • Therapy  

    Cardiovascular ...  

    Cholesterol  

  • United States  

View report >

Insulin Market and Diabetes Statistics in the US

  • March 2017
    8 pages
  • Insulin  

    Antidiabetics  

    Diabetes  

  • United States  

View report >

Diabetes Statistics

  • March 2017
    10 pages
  • Diabetes  

    Therapy  

View report >

Related Market Segments :

Therapy

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.